Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178318 | 1.00 | PTGS1 (0.53) | PTGS1PTGS2CXCR1CXCR2ALOX5 | |
| SCHEMBL2919840 | 1.00 | PTGS1 (0.53) | PTGS1PTGS2CXCR1CXCR2ALOX5 | |
| SCHEMBL11629789 | 0.82 | PTGS2 (0.41) | PTGS1PTGS2CXCR1CXCR2ALOX5 | |
| SCHEMBL3470312 | 0.82 | PTGS1 (0.39) | PTGS1PTGS2CXCR1CXCR2ALOX5 | |
| SCHEMBL21628043 | 0.82 | TYR (0.46) | PTGS2ESR1TSHR | |
| SCHEMBL2701185 | 0.81 | TSHR (0.47) | LMNAAKR1C3TSHRAKR1C2 | |
| SCHEMBL6565181 | 0.80 | PTGS1 (0.50) | PTGS1PTGS2CXCR1CXCR2ALOX5 | |
| SCHEMBL11630783 | 0.80 | ESR1 (0.45) | PTGS1PTGS2CXCR1CXCR2ALOX5 | |
| SCHEMBL10933233 | 0.80 | TSHR (0.41) | PTGS1PTGS2CXCR1CXCR2ALOX5 | |
| SCHEMBL5987622 | 0.79 | FAAH (0.37) | PTGS1PTGS2CXCR1CXCR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0766658-B1 | PROCESS FOR IMPROVING ENANTIOMERIC PURITY OF ALDEHYDES | UNION CARBIDE CHEM PLASTIC (US) | 2002-04-10 | — | — | EP | claimed |
| EP-0766658-A1 | PROCESS FOR IMPROVING ENANTIOMERIC PURITY OF ALDEHYDES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-04-09 | — | — | EP | claimed |
| WO-1996000200-A1 | PROCESS FOR IMPROVING ENANTIOMERIC PURITY OF ALDEHYDES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1996-01-04 | — | — | WO | claimed |
| US-5430194-A | Maintaining solution at temperature above eutectic temperature of mixture such that solubility limit of first aldehyde is exceeded to form crystalline first aldehyde containing less of second aldehyde | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1995-07-04 | — | — | US | claimed |
| US-11684652-B2 | HMGB1 antagonist treatment of acute lung injury | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684652-B2 | HMGB1 antagonist treatment of acute lung injury | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230149505-A1 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149505-A1 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-05-18 | — | — | US | disclosed |
| US-11524048-B2 | HMGB1 antagonist treatment of severe sepsis | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210000908-A1 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2021-01-07 | — | — | US | disclosed |
| US-20200354418-A1 | HMGB1 ANTAGONIST TREATMENT OF ACUTE LUNG INJURY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200352887-A1 | HMGB1 ANTAGONIST | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-11-12 | — | — | US | disclosed |
| US-7462731-B2 | Processes for the preparation of heterocyclic hydroxyamines and intermediates and catalysts for use therein | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2008-12-09 | — | — | US | disclosed |
| US-20050272940-A1 | Processes for the preparation of heterocyclic hydroxyamines and intermediates and catalysts for use therein | AVECIA LIMITED (GB) | 2005-12-08 | — | — | US | disclosed |
| EP-1542985-A2 | PROCESSES FOR THE PREPARATION OF HETEROCYCLIC HYDROXYAMINES AND INTERMEDIATES AND CATALYSTS FOR USE THEREIN | Avecia Limited (GB) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004024708-A2 | PROCESSES FOR THE PREPARATION OF HETEROCYCLIC HYDROXYAMINES AND INTERMEDIATES AND CATALYSTS FOR USE THEREIN | AVECIA LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| US-5270342-A | Acetamide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-14 | — | — | US | disclosed |
| EP-0254354-B1 | PHARMACEUTICALLY USEFUL DERIVATIVES OF THIAZOLIDINE-4-CARBOXYLIC ACID | ZAMBON S.p.A. (IT) | 1993-03-31 | — | — | EP | disclosed |
| US-4840936-A | ANTIFLAMMATORY, ANALGESIC AGENT TO PREVENT ARRHYTHMIAS | ZAMBON S.P.A. (IT) | 1989-06-20 | — | — | US | disclosed |
| EP-0254354-A1 | Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid | ZAMBON S.p.A. (IT) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149505-A1 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | HMGB1, HMGB3, HMGB2 | PTGS1 152/4885PTGS2 312/4885CXCR1 217/4885 |
| US-20050272940-A1 | Processes for the preparation of heterocyclic hydroxyamines and intermediates and catalysts for use therein | OXGR1, HRH3, HRH4 | PTGS1 2013/4885PTGS2 2193/4885CXCR1 170/4885 |
| US-11524048-B2 | HMGB1 antagonist treatment of severe sepsis | HMGB1, HMGB3, HMGB2 | PTGS1 152/4885PTGS2 312/4885CXCR1 217/4885 |
| US-11684652-B2 | HMGB1 antagonist treatment of acute lung injury | HMGB1, HMGB3, HMGB2 | PTGS1 229/4885PTGS2 528/4885CXCR1 134/4885 |
| US-20200352887-A1 | HMGB1 ANTAGONIST | HMGB1, HMGB3, HMGB2 | PTGS1 852/4885PTGS2 1650/4885CXCR1 92/4885 |
| US-20210000908-A1 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | HMGB1, HMGB3, HMGB2 | PTGS1 152/4885PTGS2 312/4885CXCR1 217/4885 |
| US-20200354418-A1 | HMGB1 ANTAGONIST TREATMENT OF ACUTE LUNG INJURY | HMGB1, HMGB3, HMGB2 | PTGS1 229/4885PTGS2 528/4885CXCR1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.